tyenne
fresenius kabi deutschland gmbh - tocilizumab - arthritis, rheumatoid; cytokine release syndrome; arthritis, juvenile rheumatoid; covid-19 virus infection; giant cell arteritis - leki immunosupresyjne - tyenne, in combination with methotrexate (mtx), is indicated for- the treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx. - the treatment of moderate to severe active ra in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (dmards) or tumour necrosis factor (tnf) antagonists. in these patients, tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tocilizumab has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate. tyenne is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. tyenne is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 1 year of age and older, who have responded inadequately to previous therapy with nsaids and systemic corticosteroids. tyenne can be given as monotherapy (in case of intolerance to mtx or where treatment with mtx is inappropriate) or in combination with mtx. tyenne in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (pjia; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx. tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tyenne is indicated for the treatment of chimeric antigen receptor (car) t cell-induced severe or life-threatening cytokine release syndrome (crs) in adults and paediatric patients 2 years of age and older. tyenne is indicated for the treatment of giant cell arteritis (gca) in adult patients.
kalii chloridum 0,15% + natrii chloridum 0,9% kabi (1,5 mg + 9 mg)/ml roztwór do infuzji
fresenius kabi polska sp. z o.o. - kalii chloridum + natrii chloridum - roztwór do infuzji - (1,5 mg + 9 mg)/ml
kalii chloridum 0,3% + natrii chloridum 0,9% kabi (3 mg + 9 mg)/ml roztwór do infuzji
fresenius kabi polska sp. z o.o. - kalii chloridum + natrii chloridum - roztwór do infuzji - (3 mg + 9 mg)/ml
irinotecan kabi 20 mg/ml koncentrat do sporządzania roztworu do infuzji
fresenius kabi polska sp. z o.o. - irinotecani hydrochloridum - koncentrat do sporządzania roztworu do infuzji - 20 mg/ml
octreotide kabi 50 mcg/ml roztwór do wstrzykiwań
fresenius kabi polska sp. z o.o. - octreotidi acetas - roztwór do wstrzykiwań - 50 mcg/ml
octreotide kabi 100 mcg/ml roztwór do wstrzykiwań
fresenius kabi polska sp. z o.o. - octreotidi acetas - roztwór do wstrzykiwań - 100 mcg/ml
octreotide kabi 500 mcg/ml roztwór do wstrzykiwań
fresenius kabi polska sp. z o.o. - octreotidi acetas - roztwór do wstrzykiwań - 500 mcg/ml
bendamustine kabi 2,5 mg/ml proszek do sporządzania koncentratu roztworu do infuzji
fresenius kabi polska sp. z o.o. - bendamustini hydrochloridum - proszek do sporządzania koncentratu roztworu do infuzji - 2,5 mg/ml
paracetamol kabi 10 mg/ml roztwór do infuzji
fresenius kabi polska sp. z o.o. - paracetamolum - roztwór do infuzji - 10 mg/ml
oxaliplatin kabi 5 mg/ml koncentrat do sporządzania roztworu do infuzji
fresenius kabi polska sp. z o.o. - oxaliplatinum - koncentrat do sporządzania roztworu do infuzji - 5 mg/ml